Hematologist-Oncologist: Kevin Barton, MD | Loyola Medicine

UPDATE: Power outages caused by storms have been resolved at Palos Health South Campus, Elmhurst and River Forest outpatient clinics. Palos Health South Campus has resumed appointments as scheduled. Immediate Care at River Forest will reopen today, August 12, 2020, beginning at noon. Appointments at the Elmhurst clinic will resume as scheduled on Friday, August 14.

COVID-19 (Coronavirus) Update: Learn More About Loyola Medicine Care During COVID-19.

Kevin Barton, MD

Kevin Barton, MD

Medicine

Hematology/Oncology
Professor

Languages Spoken

English
Patient Ratings
4.8 / 5 (100 Ratings)
<

Clinical Expertise

  • Amyloidosis
  • Brain Tumor
  • Cancer Of The Blood And Blood Cells
  • Leukemia
  • Lymphoma
  • Multiple Myeloma

About Dr. Barton

Interests
Astronomy

Medical Education

Medical School
The Ohio State University College of Medicine and Public Health
Residency
University of Chicago Hospitals and Clinics - Internal Medicine: General
Fellowship
  • University of Chicago Hospitals and Clinics - Internal Medicine: Hematology & Medical Oncology

Board Certification

American Board of Internal Medicine
American Board of Internal Medicine Subspecialty Hematology

Research

  • Cranial Base Meningiomas Prabhu, V. C.; Melian, E.; Germanwala, A. V.; Solanki, A. A.; Borys, E.; Barton, K.; Anderson, D. E., World neurosurgery
  • Delayed leptomeningeal metastasis of an adult anaplastic pilocytic astrocytoma Grahnke, K. A.; Heiferman, D. M.; Borys, E.; Melian, E.; Barton, K. P.; Lukas, R. V.; Shaikh, N.; Leonetti, J. P.; Anderson, D. E., BRAIN TUMOR PATHOLOGY
  • Cranial Base Meningiomas Prabhu, V. C.; Melian, E.; Germanwala, A. V.; Solanki, A. A.; Borys, E.; Barton, K.; Anderson, D. E., World neurosurgery
View All ResearchShow Less
  • Recurrent Malignant Gliomas: Treatment Options and their Effect on Patient's Quality of Life Prabhu, V. C.; Barton, K. P.; Walsh, S.; Borys, E.; Melian, E., World neurosurgery
  • The role of the Exon 13 G571S JAK2 mutation in myeloproliferative neoplasms Bahar, B.; Barton, K.; Kini, A. R., Leukemia research reports
  • Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313 Persky, D. O.; Miller, T. P.; Unger, J. M.; Spier, C. M.; Puvvada, S.; Stea, B. D.; Press, O. W.; Constine, L. S.; Barton, K. P.; Friedberg, J. W.; LeBlanc, M.; Fisher, R. I., Blood
  • Heckathorn disease revisited Nand, S.; Barton, K.; Schultz, R.; Klein, M.; Kini, A., Blood
  • Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma Stiff, P. J.; Unger, J. M.; Cook, J. R.; Constine, L. S.; Couban, S.; Stewart, D. A.; Shea, T. C.; Porcu, P.; Winter, J. N.; Kahl, B. S.; Miller, T. P.; Tubbs, R. R.; Marcellus, D.; Friedberg, J. W.; Barton, K. P.; Mills, G. M.; LeBlanc, M.; Rimsza, L. M.; Forman, S. J.; Fisher, R. I., The New England journal of medicine
  • Management of diffuse low-grade cerebral gliomas. Prabhu, V.; Khaldi, A.; Barton, K.; Melian, E.; Schneck, M. J.; Primeau, M.; Lee, J. M., Neurology Clinics
  • Precursor B-cell acute lymphoblastic leukaemia with FAB L3 (i.e. Burkitt's leukaemia/lymphoma) morphology and co-expression of monoclonal surface light chains and Tdt: report of a unique case and review of the literature, Higa, B.; Alkan, S.; Barton, K.; Velankar, M., Pathology
  • Hydroxyurea azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial, Nand, S.; Godwin, J.; Smith, S.; Barton, K.; Michaelis, L.; Alkan, S.; Veerappan, R.; Rychlik, K.; Germano, E.; Stiff, P., Leukemia & lymphoma
  • Thrombotic microangiopathy associated with sunitinib a VEGF inhibitor, in a patient with factor V Leiden mutation., Levey, S. A.; Bajwa, R. S.; Picken, M. M.; Clark, J. I.; Barton, K.; Leehey, D. J., NDT Plus
  • Blast crisis in chronic myelogenous leukemia remains a difficult therapeutic challenge Nand, S.; Barton, K., Leukemia & lymphoma
  • Expanding the pathologic spectrum of immunoglobulin light chain proximal tubulopathy. Kapur, U.; Barton, K.; Fresco, R.; Leehey, D. J.; Picken, M. M., Archives of Pathology & Laboratory Medicine
  • Management of scalp toxic epidermal necrolysis and cranial osteomyelitis with serratus anterior myocutaneous pedicle flap: a case report. Levitt, M. R.; Benedict, W. J.; Barton, K.; Melian, E.; Gamelli, R. L.; Vandevender, D.; Rosseau, G.; Prabhu, V. C., Journal of Burn Care & Research
  • Recurrent strokes in two patients with POEMS syndrome and Castleman's disease. Garcia, T.; Dafer, R. M.; Hocker, S.; Schneck, M.; Barton, K.; Biller, J., Journal of Stroke & Cerebrovascular Diseases
  • A unique case of acute promyelocytic leukemia showing monocytic differentiation after ATRA (all-trans retinoic acid) therapy. Naeem, M.; Harrison, K.; Barton, K.; Nand, S.; Alkan, S., European journal of haematology
  • Ets-1 deficiency leads to altered B cell differentiation hyperresponsiveness to TLR9 and autoimmune disease, Wang, D.; John, S. A.; Clements, J. L.; Percy, D. H.; Barton, K. P.; Garrett-Sinha, L. A., International immunology
  • Transcriptional regulation of CD1D1 by Ets family transcription factors Geng, Y.; Laslo, P.; Barton, K.; Wang, C. R., Journal of immunology (Baltimore, Md.: 1950)
  • Analysis of histone deacetylase inhibitor depsipeptide (FR901228), effect on multiple myeloma., Khan, S. B.; Maududi, T.; Barton, K.; Ayers, J.; Alkan, S., British journal of haematology
  • Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Houde, C.; Li, Y.; Song, L.; Barton, K.; Zhang, Q.; Godwin, J.; Nand, S.; Toor, A.; Alkan, S.; Smadja, N. V.; Avet-Loiseau, H.; Lima, C. S.; Miele, L.; Coignet, L. J., Blood